Advertisement

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Mar
17
Today In Oncology
Addition of Tislelizumab to Chemotherapy in Recurrent or Metastatic Nasopharyngeal Cancer
Romiplostim May Improve Chemotherapy-Induced Thrombocytopenia in Patients With GI Cancers
Women More Likely to Survive Cancer—But Suffer More Severe Side Effects
Forgotten Lessons From South Africa
Benmelstobart Plus Anlotinib in First-Line Treatment for PD-L1–Positive Advanced NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo